经导管主动脉瓣置换术超适应证使用的趋势与结局:NCDR STS/ACC TVT注册研究
超适应证TAVR占9.5%,住院死亡率(6.3% vs 4.7%)、30天死亡率(8.5% vs 6.1%)和1年死亡率(25.6% vs 22.1%)均高于适应证内使用;校正后30天死亡率仍较高(HR 1.27),但1年死亡率无显著差异(HR 1.11)。
要点
- 美国约十分之一TAVR用于超适应证,各中心比例差异大(中位6.8%,范围0%-34.7%)。
- 超适应证TAVR住院、30天和1年粗死亡率均高于适应证内使用。
- 校正后30天死亡率仍较高(HR 1.27),但1年死亡率无显著差异。
核心结论
- 美国约十分之一患者接受超适应证TAVR,校正后1年死亡率与适应证内TAVR相似。
- 超适应证TAVR校正后30天死亡率较高,需进一步研究其疗效。
研究设计与样本
- 超适应证定义为已知二叶式主动脉瓣、中度主动脉瓣狭窄、重度二尖瓣反流、重度主动脉瓣反流或主动脉瓣下狭窄。
主要发现
- 超适应证组住院死亡率6.3% vs 适应证内组4.7%(P < .001)。
- 超适应证组30天死亡率8.5% vs 6.1%(P < .001),1年死亡率25.6% vs 22.1%(P = .001)。
- 校正后30天死亡率超适应证组较高(HR 1.27;95%CI 1.04-1.55;P = .02),1年死亡率无显著差异(HR 1.11;95%CI 0.98-1.25;P = .11)。
- 各中心超适应证TAVR使用率中位6.8%(范围0%-34.7%;IQR 3.4%-12.1%),最高三分位中心30天不良心血管事件增加,但校正后无差异。
临床怎么用
- 临床实践中应关注超适应证TAVR的较高早期死亡风险,谨慎选择患者。
- 超适应证TAVR的长期疗效仍需进一步研究验证。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported. OBJECTIVE: To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice. DESIGN, SETTING AND PARTICIPANTS: Patients receiving commercially funded TAVR in the United States are included in the Transcatheter Valve Therapy Registry. A total of 23 847 patients from 328 sites performing TAVR between November 9, 2011, and September 30, 2014, were assessed for this study. Off-label TAVR was defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis. Data were linked with the Centers for Medicare & Medicaid Services for 15 397 patients to evaluate 30-day and 1-year outcomes. EXPOSURE: Off-label use of TAVR. MAIN OUTCOMES AND MEASURES: Frequency of off-label TAVR use and the association with in-hospital, 30-day, and 1-year adverse outcomes. RESULTS: Among the 23 847 patients in the study (11 876 women and 11 971 men; median age, 84 years [interquartile range, 78-88 years]), off-label TAVR was used in 2272 patients (9.5%). In-hospital mortality was higher among patients receiving off-label TAVR than those receiving on-label TAVR (6.3% vs 4.7%; P < .001), as was 30-day mortality (8.5% vs 6.1%; P < .001) and 1-year mortality (25.6% vs 22.1%; P = .001). Adjusted 30-day mortality was higher in the off-label group (hazard ratio, 1.27; 95% CI, 1.04-1.55; P = .02), while adjusted 1-year mortality was similar in the 2 groups (hazard ratio, 1.11; 95% CI, 0.98-1.25; P = .11). The median rate of off-label TAVR use per hospital was 6.8% (range, 0%-34.7%; interquartile range, 3.4%-12.1%), with hospitals in the highest tertile of off-label use associated with increased 30-day adverse cardiovascular events compared with the lowest tertile. However, this difference was not observed in adjusted 30-day or 1-year outcomes. CONCLUSIONS AND RELEVANCE: Approximately 1 in 10 patients in the United States have received TAVR for an off-label indication. After adjustment, 1-year mortality was similar in these patients to that in patients who received TAVR for an on-label indication. These results reinforce the need for additional research on the efficacy of off-label TAVR use.
引用
- Hira RS, Vemulapalli S, Li Z, et al. Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry. JAMA Cardiol. 2017. PMID: 28636718. doi:10.1001/jamacardio.2017.1685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。